Citations

Clear

9383 citation(s) found for "Thomas, PS".

Celebrating neuropathology's contributions to Alzheimer's Disease Research Centers
Fischer, D. Luke , Beach, Thomas G., Bieniek, Kevin F. , Chkheidze, Rati , Cohen, Mark L. , Crary, John F. , Dugger, Brittany N. , Dunlop, Sara , Haeri, Mohammad , Harrison, William , Head, Elizabeth, Hiniker, Annie , Huang, Eric J. , Kofler, Julia , Latimer, Caitlin S. , McKee, Ann C. , Mente, Karin , Miller, Michael B. , Montine, Thomas J., Nelson, Peter T. , Newell, Kathy L. , Perrin, Richard J., Ramani, Biswarathan , Reichard, R. Ross , Roy, Subhojit , Schlachetzki, Johannes C. M. , Wısnıewskı, Thomas , Lee, Edward B. , Head, Elizabeth , Dunlop, Sara R, Dugger, Brittany N , Lee, Edward B , Head, Elizabeth , Grinberg, Lea T. , Ahrendsen, Jared T. , Beach, Thomas G., Castellani, Rudolph J. , Cobos, Inma , Dickson, Dennis W. , Farrell, Kurt , Ghetti, Bernardino , Hüttner, Anita , Jamshidi, Pouya , Kapasi, Alifiya , Keene, C. Dirk , Miller, Michael B., Montine, Thomas J., Morris, Meaghan , Murray, Melissa E. , Seeley, William W. , Serrano, Geidy E. , Spina, Salvatore , Teich, Andrew F. , Wang, Shih‐Hsiu J.

Mayo Clinic

Alzheimer's & Dementia | October 14, 2025 | Volume: 21 | Issue: 10 | Pages: No page available

10.1002/alz.70734 | PMID 41085158 Get It

Abstract Our understanding of Alzheimer's disease (AD) and related dementias (ADRD) has grown exponentially, thanks to significant investments by the National Institute on Aging (NIA). This article celebrates the 40th anniversary of the NIA's Alzheimer's Disease Research Centers, highlighting the pivotal role of neuropathology as the bedrock for neurodegeneration research. Neuropathology has championed the key principles of proteinopathy, selective vulnerability, and stereotypic spread. Furthermore, neuropathologic studies advanced our understanding of ADRD prevalence, heterogeneity, clinical–pathological correlations, and genetic underpinnings, spurring biomarker development for target engagement and disease monitoring. Disease‐modifying therapies for AD were inspired and informed by neuropathology. The neuropathology community is poised to refine diagnostics, leveraging digital pathology and integrating genetics and pathomics to enhance subtyping for novel precision medicine approaches. Despite some common misconceptions and logistical challenges, neuropathology continues to be a critical component of the ADRD research infrastructure, serving as a key bridge between allied basic and clinical sciences. Highlights We celebrate 40 years of NIA‐funded ADRCs and their contributions through neuropathology studies that have significantly advanced our understanding and treatment of ADRD. Neuropathology uncovers principles of neurodegenerative disease: proteinopathy, selective vulnerability, and stereotypic spread, informing diagnostics and therapies. Development of AD biomarkers with reference to neuropathology enhances accuracy in diagnosis and monitoring, paving the way for targeted disease‐modifying therapies. Integration of digital pathology, genetics, and novel tools in neurodegeneration research promises advanced precision medicine approaches and refined diagnostics. Misconceptions and logistical challenges to neuropathological research are addressed to improve understanding and collaboration.
Does the Timing of Lysis of Adhesions After Anterior Cruciate Ligament Reconstruction Affect Final Range of Motion?
Miltenberg, Benjamin , Jurgensmeier, Kevin , Davis, Gaston, Tagliero, Adam J. , Freedman, Kevin B. , Krych, Aaron J. , Cohen, Steven A. , Schneble, Christopher A , Miltenberg, Benjamin , Jurgensmeier, Kevin , Tagliero, Adam , Krych, Aaron J

Mayo Clinic

The American Journal of Sports Medicine | October 14, 2025 | Volume: 53 | Issue: 14 | Pages: 3426-3434

10.1177/03635465251383162 | PMID 41321088 Get It

Background: Arthrofibrosis is seen in 1.7% to 38% of patients after anterior cruciate ligament reconstruction (ACLR) and has been associated with worse postoperative patient-reported outcomes. There are limited data regarding the optimal time to intervene in cases of arthrofibrosis after ACLR. Purpose: To assess if timing of arthrofibrosis treatment after ACLR affects final knee range of motion (ROM) and to help establish guidelines with regard to timing of intervention for arthrofibrosis after ACLR. Study Design: Cohort study; Level of evidence, 3. Methods: Databases were retrospectively screened at 2 high-volume practices for patients who underwent lysis of adhesions (LOA; Current Procedural Terminology [CPT] 29884 and 29875) with or without manipulation under anesthesia (CPT 27570) after ACLR (CPT 29888). Clinical ROM assessments were collected at multiple time points. Patients were grouped into cohorts based on timing of LOA. Comparative analysis was performed to assess for relationships between ROM and timing of intervention. Results: Seventy-nine patients underwent LOA after ACLR: 25 patients who had a time from ACLR to LOA <3 months, 23 patients between 3 and 6 months, and 31 patients >6 months. Earlier LOA was associated with greater total loss of motion before LOA. The final total arc of motion was 132.7°, 133.7°, and 131.8° for patients who had a time from ACLR to LOA <3 months, between 3 and 6 months, and >6 months, respectively. There were no significant differences among groups in final flexion ( P = .8), extension ( P = .746), or total arc of motion ( P = .781). Linear regression modeling did not identify time from ACLR to LOA as a predictive variable ( P = .982) in final ROM. Conclusion: This study failed to demonstrate a linear relationship between the timing of LOA and final ROM. Regardless of the time to intervention, ROM improved significantly; however, patients with more severe arthrofibrosis underwent LOA at earlier time points.
A practical guide to the updated seizure classification 2025
Trinka, Eugen , Blumenfeld, Hal , Fressola, Alicia Bogacz , Cendes, Fernando , Frauscher, Birgit , Jansen, Floor E. , Kahane, Philippe , Kander, Veena , Lizcano, Angélica , Ryvlin, Philippe , Tatum, William O. , Yacubian, Elza Márcia Targas , Wilmshurst, Jo M. , Cross, J. Helen , Beniczky, Sándor , Trinka, Eugen , Cendes, Fernando , Frauscher, Birgit , Kander, Veena , Kishk, Nirmeen , Khoo, Ching Soong , Lizcano, Angelica , Ryvlin, Philippe , Wilmshurst, Jo M , Cross, Helen J , Wirrell, Elaine , Singh, Mamta Bhushan , Craiu, Dana , De Palma, Luca , Specchio, Nicola , Sperling, Michael R.

Mayo Clinic

Epileptic Disorders | October 14, 2025 | Volume: 27 | Issue: 6 | Pages: 1087-1104

10.1002/epd2.70110 | PMID 41081650 Get It

Abstract This paper provides a practical guide to applying the updated seizure classification in clinical settings. The updated classification, published by the International League Against Epilepsy in 2025, builds on the operational classification introduced in 2017. It aims to enhance clarity, clinical relevance, and consistency in seizure terminology across various healthcare settings. The classification system distinguishes between four main seizure classes: focal, generalized, unknown whether focal or generalized, and unclassified. The basic version allows for application even in resource‐limited or primary care environments, while the expanded version offers detailed semiological descriptors and supports advanced diagnostic and surgical decision‐making. Consciousness, defined through awareness (recall) and responsiveness, is now considered a classifier. The paper also highlights the importance of distinguishing observable from non‐observable features and integrates semiology into the expanded classification with attention to temporal sequence and somatotopic detail. Generalized seizures are categorized into seizure types having a direct impact on syndrome diagnosis and treatment decisions. Epileptic spasms are given special attention because of their unique presentation and the urgency of early intervention, particularly in infants. To support clinical implementation, this paper includes a comprehensive table of semiological descriptors, definitions of generalized seizure types, and a series of real‐world case vignettes illustrating the application of the updated seizure classification. Supplementary figures and videos further support the educational aims of the paper. This practical guide is intended for healthcare professionals managing patients with epilepsy, providing a clear, structured approach to seizure classification that is adaptable to varying levels of clinical expertise and diagnostic resources.
Rare but Relevant? Assessing Variants in Dystonia‐Linked Genes in Parkinson's Disease
Screven, Laurel A. , Tan, Ai Huey , Fenn, Matilda, Frost, Joshua L.I., Jankovic, Joseph, Jasaityte, Simona , Jeon, Beomseok , Sarmiento, Ignacio Juan Keller , Krüger, Rejko , Kuhlenbäumer, Gregor , Schirinzi, Tommaso , Shulman, Joshua M., Uitti, Ryan J. , Wu, Lesley , Zeuner, Kirsten E., Blauwendraat, Cornelis , Singleton, Andrew, Lohmann, Katja , (GP2), the Global Parkinson's Genetics Program, Tan, Ai Huey , Jeon, Beom Seok , Lin, Chin-Hsien , Schirinzi, Tommaso , Shin, Jung Hwan , Tay, Yi Wen , Uitti, Ryan, Warner, Thomas T. , Wszolek, Z.K. , Wu, Ruey-Meei , Blauwendraat, Cornelis , Morris, Huw R , Lohmann, Katja , Lange, Lara Mariah , Fang, Zih‐Hua , Alcalay, Roy N. , Amouri, Rim , Bovenzi, Roberta , Frost, Joshua L.I., Jankovic, Joseph J. , Jaunmuktane, Zane , Lin, Chin‐Hsien , Pavelka, Lukas , Periñán, María Teresa , Sassi, Samia Ben , Shulman, Joshua M. , Wszołek, Zbigniew K. , Wu, Ruey‐Meei , Singleton, Andrew , Mencacci, Niccolò Emanuele , Morris, Huw R. , Lim, Shen‐Yang , Klein, Christine , (GP2), the Global Parkinson's Genetics Program

Mayo Clinic

Movement Disorders | October 11, 2025 | Volume: 41 | Issue: 1 | Pages: 247-259

10.1002/mds.70073 | PMID 41074695 Get It

Abstract Background Dystonia and Parkinson's disease (PD) exhibit clinical and genetic overlap, but the relevance of dystonia gene variants in PD remains unclear. Objective The aim was to assess the frequency of dystonia‐linked pathogenic variants in PD. Methods We screened sequencing data from 15,684 individuals (8272 PD, 3200 atypical parkinsonism, and 4212 unaffected) from the Global Parkinson's Genetics Program (GP2) and Accelerating Medicines Partnership‐Parkinson's Disease (AMP‐PD) for variants in genes linked to isolated dystonia, dystonia‐parkinsonism, and myoclonus‐dystonia. Results Pathogenic variants were identified only in PD patients. Forty‐five PD individuals (0.54%) carried 26 distinct (likely) pathogenic variants in nine dystonia‐linked genes, most frequently in GCH1 , followed by VPS16 . Conclusion Though rare, pathogenic variants in dystonia‐linked genes are present in clinically and pathologically diagnosed PD. Our results reinforce GCH1 as a PD‐relevant gene with clinical implications, whereas variants identified in other genes are rare and of uncertain relation to the PD phenotype. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Methylation-induced suppression of YAP/TAZ confers sensitivity to HDAC inhibitors in high-grade IDH mutant gliomas
Sears, Thomas , Wang, Wenxia , Steffens, Alicia , McCortney, Kathleen , Horbinski, Craig , Horbinski, Craig , McCortney, Kathleen , Sears, Thomas , McCord, Matthew , Chaliparambil, Rahul Kishore , Sarkaria, Jann N.

Mayo Clinic

JCI Insight | October 9, 2025 | Volume: 10 | Issue: 22 | Pages: No page available

10.1172/jci.insight.195385 | PMID 41066183 Get It

IDH1/2 mutations (IDH mut ) increase methylation of DNA and histones in gliomas. IDH mut inhibitors are effective against low-grade IDH mut gliomas, but new strategies against high-grade IDH mut gliomas are needed. Although histone deacetylase inhibitors (HDACi) are ineffective against IDH wt glioblastoma (GBM), their potential in IDH mut gliomas has not been extensively studied. We previously established that IDH mut gliomas are more sensitive to HDACi than IDH wt GBM. Here we show that IDH mut is associated with greater sensitivity to HDACi only in glioma, not in IDH mut chondrosarcoma or cholangiocarcinoma. While HDACi induced more histone acetylation and gene regulation in IDH mut glioma than in IDH wt GBM, such acetylation was mostly within gene deserts, whereas IDH mut glioma promoters paradoxically lost histone acetylation. Two mediators of HDACi resistance, YAP and TAZ, were methylated and suppressed in IDH mut gliomas but not in other IDH mut cancers. Inducing YAP or TAZ expression in IDH mut gliomas conferred resistance to HDACi. Finally, belinostat extended in vivo survival only in IDH mut glioma models, not in IDH mut GBM models. Our findings provide a mechanistic rationale for further studies of HDACi in patients with IDH mut glioma, as well as the potential use of YAP/TAZ as a biomarker of HDACi sensitivity in cancers.
NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025
Advani, Ranjana H. , Andreadis, B., Chang, Julie , Christian, Beth , deVos, Sven, Fayad, Luis , Hamid, Muhammad Saad , Hernandez‐Ilizaliturri, Francisco J. , Karimi, Yasmin , King, Rebecca L. , Krivacic, Susan, LaCasce, Ann S. , Messmer, Marcus , Rabinovitch, Rachel , Roberts, Kenneth B. , Saito, Naoyuki G. , Smith, Stephen D. , Swinnen, Lode J., Tuscano, Joseph M. , Dwyer, Mary A., Sundar, Hema, Advani, Ranjana H , Karimi, Yasmin H , Zelenetz, Andrew D. , Gordon, Leo I. , Abramson, Jeremy S. , Bartlett, Nancy L. , Budde, Lihua E. , Caimi, Paolo F. , Dholaria, Bhagirathbhai , Habermann, Thomas M. , Hu, Boyu , Kelsey, Chris R. , Kline, Justin Paul , Landsburg, Daniel J. , Lim, Megan S. , Ramakrishnan, Praveen , Reid, Erin G , Saeed, Hayder , Vose, Julie M.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | October 9, 2025 | Volume: 23 | Issue: 10 | Pages: No page available

10.6004/jnccn.2025.0048 | PMID 41067277 Get It

The treatment landscape of B-cell lymphomas has significantly evolved in recent years with approval of novel targeted therapies. CD3 × CD20 bispecific antibodies and CD19-directed monoclonal antibodies and antibody–drug conjugates have demonstrated efficacy in relapsed/refractory follicular lymphoma (FL). Bruton tyrosine kinase (BTK) inhibitor–based regimens are emerging as effective treatment options for patients with TP53-mutated classical mantle cell lymphoma (MCL). Results from ongoing clinical trials suggest that the addition of CD3 × CD20 bispecific antibodies to chemoimmunotherapy improves outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). These NCCN Guideline Insights highlight significant updates to the NCCN Guidelines for B-Cell Lymphomas for the treatment of FL, MCL, and DLBCL.
Hematopoietic Cell Transplantation, Version 3.2025, NCCN Clinical Practice Guidelines In Oncology
Loren, Alison W. , Bolaños‐Meade, Javier , Brammer, Jonathan E. , Cowden, Meredith , Stasi, Antonio Di , El‐Jawahri, Areej , Elmariah, Hany , Gundabolu, Krishna , Gutman, Jonathan A. , Ho, Vincent T. , Hoeg, Rasmus T. , Horwitz, Mitchell E. , Jamy, Omer , Dabaja, Mohamed Kharfan, Lee, Lauren , Luszcak, Christina, Magenau, John, Martin, Thomas , Mittal, Varun , Moreira, Jonathan , Muffly, Lori , Nakamura, Ryotaro , Nawas, Mariam, Ninos, Cameron , Oliai, Caspian , Pidala, Joseph A. , Randolph, Brion, Tessier, Jeffrey, Topal, Jeffrey , Varshavsky‐Yanovsky, Asya, Jones, Frankie, Stehman, Katie, Elmariah, Hany , Jamy, Omer , Muffly, Lori , Mielcarek, Marco B. , Kassim, Adetola A , Logan, Aaron C , Nawas, Mariam T. , Nieto, Yago , Oliai, Caspian H , Papanicolaou, Genovefa A. , Schroeder, Mark A. , Tzachanis, Dimitrios

Mayo Clinic

Journal of the National Comprehensive Cancer Network | October 9, 2025 | Volume: 23 | Issue: 10 | Pages: No page available

10.6004/jnccn.2025.0047 | PMID 41067275 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Hematopoietic Cell Transplantation (HCT) provide expert, multidisciplinary recommendations for autologous and allogeneic HCT based on current evidence. The NCCN Guidelines focus on pretransplant recipient evaluation, hematopoietic cell mobilization, conditioning, and the diagnosis and management of graft-versus-host disease (GVHD), a common complication of allogeneic HCT that is associated with significant morbidity. This selection from the NCCN Guidelines for HCT focuses on the diagnosis, workup, and management of acute and chronic GVHD, as well as important supportive care considerations.
Abstract Thu133: Discovery of a Novel Compound Targeting CDCP1 to Modulate Human Cardiac Fibrosis
Srinivas, Akshatha Narayanrao, Wang, Min , Zhang, Heyu , Weber, Caleb, Islam, Naeyma N., Fuller, Jessica , Lambert, Laura , Weinshilboum, Richard M. , Pereira, Naveen L. , Ghazal, Rachad , Srinivas, Akshatha Narayanrao, Selvaraj, Manikandan , Marín-Goñi, Irene , Coban, Matt , Weber, Caleb, Fuller, Jessica, Liu, Duan , Lambert, Laura, Weinshilboum, Richard M. , Caulfield, Thomas R.

Mayo Clinic

Circulation Research | October 8, 2025 | Volume: 137 | Issue: Suppl_1 | Pages: No page available

10.1161/res.137.suppl_1.thu133 Get It

Background: Cardiac fibrosis is a central pathological process that leads to worse outcomes in various cardiomyopathies. Recent evidence shows that CDCP1 (CUB domain-containing protein 1) modulates myocardial recovery by attenuating human cardiac fibroblast (HCF) proliferation. This study investigates the hypothesis that selective targeting of the CDCP1 cleavage domain can mitigate fibroblast proliferation, thereby offering a novel therapeutic approach to reducing cardiac fibrosis. Methods: A high-throughput in silico screening was performed using the Enamine compound library, focusing on structural regions that include the cleavage and adjacent sites of CDCP1 . A total of 147 candidate compounds were prioritized based on docking scores and binding stability profiles. Selected compounds were subsequently evaluated in vitro using HCF cultures seeded at 3,000 cells/well in 96-well plates. Each compound was administered at 10 μM concentration, and cell proliferation and viability were assessed by time-lapse imaging in the Incucyte® system at 24 and 96 hours. All experiments were done in triplicate with appropriate DMSO vehicle controls. Results: Compound C3 significantly reduced HCF proliferation (Fig B) to 27.3±2.4% relative to DMSO controls (99.9±0.5%, P <0.001) at 96 hours. Detailed structural modeling indicated that C3 binds to the CDCP1 cleavage site (Fig C) with a favorable Glide XP docking score of -7.66 kcal/mol. The interaction is stabilized by hydrogen bonds with Lys365 and Cys374 (Fig D), and supplementary hydrophobic interactions between aromatic rings and aliphatic groups, which contribute to a strong inhibitory effect. Conclusion: Targeting the CDCP1 cleavage domain with compound C3 effectively diminishes HCF proliferation in vitro. Therefore, these results substantiate the therapeutic potential of CDCP1 inhibition in cardiac fibrosis. Ongoing in vivo studies will explore the translational relevance of these findings.
Digital Planning-Based Technologies to Support Memory-Related Functioning in Older Adults with Mild Cognitive Impairment: A Systematic Scoping Study
Sriranganathan, Aswen , Kathiravelu, Shaylene, Sikora, Lindsey , McClymont, Shekinah, Locke, Dona E.C. , Chandler, Melanie , Shandera‐Ochsner, Anne L., Chan, Adrian D. C. , Rajabiyazdi, Fateme , Santos, Octavio A. , Trudel, Chantal , Jaiswal, Atul , Thomas, Neil , Locke, Dona E C , Li, Tracy

Mayo Clinic

Journal of Ageing and Longevity | October 8, 2025 | Volume: 5 | Issue: 4 | Pages: 42

10.3390/jal5040042 Get It

Background: Mild cognitive impairment (MCI) is a precursor to dementia, with a prevalence of over 15% among community dwellers, with significant economic and social implications. Despite preserved autonomy in daily living, individuals with MCI face challenges in handling everyday technology and memory-related tasks, necessitating digital interventions, such as digital planning-based technologies to support cognitive functioning. Objective: The aim of this study is to identify and summarize available research literature on available digital planning-based technologies to support memory-related functioning in older adults with MCI. Specifically, this study seeks to (1) document the types and functions of these technologies, (2) report their effectiveness, and (3) identify gaps in the current evidence. Methods: A comprehensive literature search of four databases (Medline, Embase, APA PsycINFO, and CINAHL) was conducted in accordance with Arksey and O’Malley’s scoping review methodological framework from inception to February 6, 2024, without restrictions. Inclusion criteria focused on peer-reviewed studies involving adults aged 50 or older with diagnosed cognitive impairment, specifically using digital planning-based technologies for memory support. Results: From 1854 sources, 8 studies were included. Five categories of digital planning-based technologies were identified: (1) reminders and alarms, (2) electronic calendars, (3) digital memory notebooks, (4) digital visual mapping, and (5) smart-home integration. Several studies reported improved task performance, memory recall, and executive function, with digital memory notebooks and visual mapping software showing greatest impact on functional independence. While interventions were generally well-received, usability challenges and low adherence were common, often linked to technological familiarity and motivation. Conclusions: Digital planning-based technologies show promise in supporting memory-related functioning in older adults with MCI. While studies report positive outcomes, more research is needed to refine these tools, evaluate long-term effects, and ensure integration into daily life. Expanding the evidence base will be key to improving accessibility and effectiveness for this population.